Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),
(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2
(Amendment No. __)*
GT Biopharma, Inc.
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
36254L209
(CUSIP Number)
June 30, 2023
Date of Event Which Requires Filing of this Statement
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
0 Rule 13d-1(b)
1 Rule 13d-1(c)
0 Rule 13d-1(d)
________________
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act, but shall be subject to all
other provisions of the Act (however, see the Notes).
CUSIP No. 36254L209
1) Name of Reporting Person Cytovance Biologics, Inc.
2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) 0
(b) 0
3) SEC Use Only
4) Cititzenship or Place of Origin Delaware
Number of Shares 5) Sole Voting Power 2,755,817
Beneficially Owned
By Each Reporting 6) Shared Voting Power 0
Person With
7) Sole Dispositive Power 2,755,817
8) Shared Dispositive Power 0
9) Aggregate Amount Beneficially Owned by Each Reporting Person 2,755,817
10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) 0
11) Percent of Class Represented by Amount in Row 9 6.8%
12) Type of Reporting Person (See Instructions) CO
Item 1(a) Name of Issuer
GT Biopharma, Inc.
Item 1(b) Address of Issuer's Principal Executive Offices
8000 Marina Blvd, Suite 100
Brisbane, CA 94005
Item 2(a) Name of Person Filing
Cytovance Biologics, Inc.
Item 2(b) Address of Principal Business Office or, if None, Residence
800 Research Parkway, Suite 200
Oklahoma City, OK 73104
Item 2(c) Citizenship
Delaware
Item 2(d) Title of Class of Securities
Common Stock, par value $0.001
Item 2(e) CUSIP Number
36254L209
Item 3. Filing Status if filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c)
Not applicable.
Item 4. Ownership
(a) Amount Beneficially Owned: 2,755,817
(b) Percent of Class: 6.8% (1)
(c) Number of Shares as to Which Such Person Has:
(i) Sole Power to Vote or to Direct the Vote: 2,755,817
(ii) Shared Power to Vote or to Direct the Vote: 0
(iii) Sole Power to Dispose or Direct the Disposition of: 2,755,817
(iv) Shared Power to Dispose or Direct the Disposition of: 0
(1) Based on 40,639,688 shares of Common Stock outstanding as of
August 7, 2023, as disclosed by GT Biopharma, Inc. in its Form 10-Q filed
with the Securities and Exchange Commission on August 7, 2023.
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of Members of the Group.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of a Group.
Not applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having
that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
CYTOVANCE BIOLOGICS, INC.
By /s/ David Knauss
Name: David Knauss
Title: Secretary and Treasurer
Date: September 18, 2023